Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model

International Journal of Ophthalmology

Volumn 5, Issue 4, 2012, Pages 448-451

  Dursun, Ayhan ^a   Arici, Mustafa Kemal ^a   Dursun, Feyza ^a   Ozec, Ayse Vural ^a   Toker, Mustafa Ilker ^a   Erdogan, Haydar ^a   Topalkara, Aysen ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Corneal neovascularisation; Ranibizumab

Indexed keywords

EID: 84875739908     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2012.04.08     Document Type: Article

References (24)

1. Chang JH, Gabison EE, Kato T, Azar DT Corneal neovascularization. Curr Opin Ophthalmol. 2001;12(4):242-249.
2. Dana MR, Schaumberg DA, Kowal V.O., Goren MB, Rapuano CJ, Laibson PR, Cohen EJ Corneal neovascularization after penetrating keratoplasty. Cornea. 1995;14(6):604-609.
3. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41(9):2514-2522.
4. Manzano RP, Peyman GA, Khan P, Carvounis P.E., Kivilcim M., Ren M, Lake JC, Chevez-Barrios P. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin) Br J Ophthalmol. 2007;91(6):804-807.
5. Bock F, Onderka J, Dietrich T., Bachmann B, Kruse FE, Paschke M, Zahn G., Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48(6):2545-2552.
6. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328-335.
7. Rosenfeld PJ, Brown DM, Heier J.S., Boyer DS, Kaiser PK, Chung CY, Kim RY Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
8. Kwon YS, Hong HS, Kim J.C., Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005;46(2):454-460.
9. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O., Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P. Tubingen bevacizumab study group: safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86(3):322-328.
10. Usui T, Ishida S, Yamashiro K., Kaji Y, Poulaki V, Moore J., Moore T, Amano S, Horikawa Y, Dart D, Golding M, Shima DT, Adamis AP. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004;45(2):368-374.
11. Eng KT, Kertes PJ Ranibizumab in neovascular age-related macular degeneration. Clin Interv Aging. 2006;1(4):451-466.
12. Brown DM, Michels M, Kaiser P.K., Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.
13. Rosenfeld PJ, Brown DM, Heier J.S., Boyer DS, Kaiser PK, Chung CY, Kim R.Y., MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
14. Dursun A, Arici MK, Ozec A.V., Dursun F., Toker MI, Topalkara A. Application of Topical/Subconjunctival Bevacizumab and Topical Fluorometholone Acetate in Alkali Burn-induced Model of Corneal Angiogenesis. Turk J Ophthalmol. 2010;40(6):318-322.
15. Bock F, König Y, Kruse F., Baier M, Cursiefen C. Bevacizumab eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008;246(2):281-284.
16. Ahmed A, Berati H, Nalan A., Aylin S. Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Experiment Ophthalmol. 2009;37(7):730-736.
17. Feiner L, Barr EE, Shui Y.B., Holekamp NM, Brantley MA, Jr Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006;26(8):882-888.
18. Spitzer MS, Wallenfels-Thilo B, Sierra A., Yoeurek E, Peters S, Henke-Fahle S, Bartz-Schmidth KU, Szurman P. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90(10):1316-1321.
19. Luthra S, Narayanan R, Marques L.E., Chwa M., Kim DW, Dong J, Seigel GM, Neekhra A, Gramajo A.L., Brown DJ, Kenney MC, Kuppermann BD. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 2006;26(5):512-518.
20. Fuh G, Wu P, Liang W.C., Ultsch M., Lee CV, Moffat B, Wiesmann C. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281(10):6625-6631.
21. Hosseini H, Nejabat M, Mehryar M., Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol. 2007;35(8):745-748.
22. Hurmeric V, Erdurman CF, Mumcuoglu T, Kurt B., Dagli O, Karaca U, Durukan HA Comparison of the Effect of Subkojunctival Bevacizumab and Pegaptanib Sodium in an Experimental Corneal Neovascularisation. Turk J Ophthalmol. 2009;39(5):349-354.
23. Habot-Wilner Z., Barequet IS, Ivanir Y, Moisseiev J., Rosner M. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophtalmol. 2010;88(8):862-867.
24. You IC, Kang IS, Lee S.H., Yoon KC Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009;87(6):653-658.